This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary Chimeric Antigen Receptor B-Cell (CAR-B) Therapy Development
Most veterinary CAR therapies primarily focus on T cells. However, as research progresses, it is becoming evident that various other immune cells could also be utilized to transport CAR. BioVenic is dedicated to collaborating with scientists globally to create CAR versions of these animal immune cells and assess their capacity to identify and eliminate tumor cells. Our team of experts utilizes a professional animal cell transformation platform to transform B cells adaptively and transduce CAR to enhance their application in cancer treatment for companion animals. Animal B cells possess a range of anti-tumor functions, including antibody production, antigen presentation to T cells, and direct killing of tumor cells or production of related enzyme proteins. We offer a comprehensive solution for veterinary CAR-B cell therapy development and assess the efficacy of killing various tumors. Additionally, we assist in advancing combined cell therapy by integrating CAR-B cells and CAR-T cells to enhance treatment effectiveness.
Fig.1 B cell ontogeny.1,2
Comparison of B Cells and T Cells
| B Cells | T Cells | |
| Origin | Originates and matures in the bone marrow | Originates in the bone marrow and matures in the thymus |
| Lifespan | Shorter | Longer |
| Secretion | Antibodies | Cytokines |
| Membrane Receptor | BCR | TCR |
| Immunity Type | Antibody-mediated Humoral Immunity | Cell-mediated Immunity |
Veterinary CAR-B Therapy Development Services
Research on the chimeric antigen receptor (CAR) version of B cells is still in its early stages. BioVenic offers a comprehensive range of customized services to address key technical challenges, such as genetic engineering and CAR transduction, involved in the advancement of veterinary CAR-B cell therapy.
- Therapeutic Development Support
CAR design and construction are fundamental steps in the development of CAR-B cell therapy. BioVenic specializes in CAR discovery, design, and construction, integrating various gene and protein analysis technologies to identify disease biomarkers as potential therapeutic targets. This approach aims to achieve the most suitable molecular design for specific functions. Our expert team meticulously develops standardized service processes for CAR-B in vitro tests, which include CAR expression verification, cytokine screening, cytotoxicity assessments, cell proliferation studies, and other related tests. This comprehensive suite of services provides clients with robust tools for the scientific evaluation of CAR-B cells for preclinical veterinary applications.
- Genome Modification
BioVenic assists customers with genome-level engineering projects focused on B cells for the development of veterinary CAR therapies. We offer advanced CRISPR/Cas9 technology support for animal cell gene editing, which is utilized in conjunction with other methods to execute effective knockout projects in therapy development. By modifying the genome, the expression of endogenous B cell receptors in animal B cells can be eliminated, enhancing their suitability for veterinary cell therapy.
Why Choose Us?
Expertise in Cell Modification
Our team of experts possesses extensive experience and a profound professional background in designing and developing CAR constructs, as well as modifying immune cells to express these specific CARs.
Combination of CAR-B and CAR-T
We offer comprehensive technology for developing veterinary immune cell therapies, helping our clients to create innovative CAR-B and CAR-T combination treatment solutions that enhance the effectiveness of these therapies.
One-Stop CAR Therapy Development
We are dedicated to offering our customers comprehensive technical services throughout the entire process, from development to evaluation. Our services include disease marker identification, CAR construction, and in vitro testing, all aimed at accelerating the overall project development timeline.
BioVenic continues to focus on cutting-edge advancements in veterinary immunotherapy. Following the remarkable success of CAR-T cell therapy in treating tumors in companion animals, we have broadened our development vision and technical focus to include other immune cells, particularly B cells. Through genetic modification, CAR construction, and exogenous gene expression, we transform immune cells to enhance their ability to identify and combat tumor cells. We offer a comprehensive range of services for researchers currently exploring veterinary therapies and developing B-cell immunotherapy programs, including engineering B cells to express a specific CAR and supporting a series of in vitro tests for evaluation. If you are encountering challenges in your scientific research in this field, please do not hesitate to contact us!
References
- Image retrieved from Figure 1 "Human B cell ontogeny." Sanz et al., 2019, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). The original title was changed to "B cell ontogeny."
- Sanz, Ignacio, et al. "Challenges and opportunities for consistent classification of human B cell and plasma cell populations." Frontiers in immunology 10 (2019): 2458.